Medicine and Dentistry
Lutetium 177
83%
Dosimetry
50%
Radionuclide Therapy
47%
Absorbed Dose
41%
Prostate Cancer
40%
Neoplasm
36%
Peptide Receptor
21%
Tetraxetan
19%
Prostate Specific Membrane Antigen
18%
Neuroendocrine Tumor
16%
Combination Therapy
14%
Targeted Radionuclide Therapy
13%
Dose Response
12%
DNA Damage
12%
Somatostatin Receptor
11%
Radiation Biology
10%
Microsphere
10%
Radioisotope
10%
Biodistribution
10%
Albumin
10%
Clinical Trial
9%
Actinium 225
9%
Yttrium 90
9%
Polyethylene Terephthalate
9%
Radioembolization
8%
Positron Emission Tomography
8%
Nuclear Medicine
8%
Tumor Cell
8%
Gallium 68
7%
Single Photon Emission Computed Tomography-Computed Tomography
7%
Radioligand
7%
Nephrotoxicity
7%
Xenograft
6%
Salivary Gland
6%
Metastatic Carcinoma
6%
Radioactive Tracer
6%
Affibody Molecule
6%
Positron Emission Tomography-Computed Tomography
6%
Treatment Response
6%
Radiopharmaceutical
5%
Bone Marrow Toxicity
5%
Indium 111
5%
Gastrin Releasing Peptide Receptor
5%
Magnetic Resonance Imaging
5%
Holmium
5%
Experimental Therapy
5%
Single-Photon Emission Computed Tomography
5%
Pharmacology, Toxicology and Pharmaceutical Science
Lutetium 177
100%
Radioisotope
64%
Dosimetry
47%
Prostate Cancer
41%
Neoplasm
40%
Prostate Specific Membrane Antigen
28%
Receptor
27%
Neuroendocrine Tumor
25%
Tetraxetan
23%
Actinium 225
19%
Polyethylene Terephthalate
18%
Radioligand
18%
Biodistribution
15%
Combination Therapy
14%
Somatostatin Receptor
12%
Clinical Trial
10%
Albumin
9%
Clinical Dosimetry
8%
Gastrin Releasing Peptide Receptor
8%
Diseases
7%
Tracer
7%
Lead 203
7%
Yttrium 90
6%
Nephrotoxicity
6%
Gallium 68
6%
Indium 111
6%
Cholecystokinin B Receptor
6%
Preclinical Study
5%
Bone Marrow Toxicity
5%
Pharmacokinetics
5%
Organ Toxicity
5%
Lead 212
5%